TOKYO, Dec. 21, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 trial of XOSPATA® (gilteritinib) plus ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said that a phase 3 confirmatory trial of XOSPATA or gilteritinib in patients with relapsed (disease that has returned) or refractory (resistant to ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

Hypersensitivity to Gilteritinib or any of the excipients. What if you Miss a Dose of Gilteritinib? If a dose of Gilteritinib is missed or not taken at the routine time, it should be taken as soon as ...

MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop ...

Review the side-effects of Gilteritinib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with ...

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or ...

(HealthDay)—For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in ...

A paradigm shift is underway in the treatment of acute myeloid leukemia: The newest of personalized medicines proved more effective and less toxic than standard chemotherapy for certain acute myeloid ...